<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 13 Apr 2021 19:19:17 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>AACR年度学者公布：王晓东、陈列平入选</title><link>https://mp.weixin.qq.com/s/khmu2Gyos97f2zzAe6JErg</link><description></description><content:encoded><![CDATA[AACR年度学者公布：王晓东、陈列平入选]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>华东医药“少女针”获批？</title><link>https://mp.weixin.qq.com/s/yIowbwIg4SOZxkIzFvjxKg</link><description></description><content:encoded><![CDATA[华东医药“少女针”获批？]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>“新华—崇明”医联体集采结果出炉，仅9个品种拟中选</title><link>https://mp.weixin.qq.com/s/rI5WBDpNioltP84O_CfNZQ</link><description></description><content:encoded><![CDATA[“新华—崇明”医联体集采结果出炉，仅9个品种拟中选]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>百济神州公布替雷利珠单抗 vs 化疗治疗NSCLC临床数据</title><link>https://mp.weixin.qq.com/s/WO-wHWYfyWY-ZHmzm-Z1fA</link><description></description><content:encoded><![CDATA[百济神州公布替雷利珠单抗 vs 化疗治疗NSCLC临床数据]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>FibroGen抗CTGF单抗获FDA快速通道资格认定</title><link>https://mp.weixin.qq.com/s/NXpaKzbHe49ctavtM48LIw</link><description></description><content:encoded><![CDATA[FibroGen抗CTGF单抗获FDA快速通道资格认定]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>亚盛医药公布5个在研原创新药最新临床进展</title><link>https://mp.weixin.qq.com/s/BxFr-fsU3uVwlT9YCN07Qg</link><description></description><content:encoded><![CDATA[亚盛医药公布5个在研原创新药最新临床进展]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>AACR重磅：PROTAC分子 ARV-110 、ARV-471结构公布</title><link>https://mp.weixin.qq.com/s/C03-ranwU03Yl7mxdGpNiQ</link><description></description><content:encoded><![CDATA[AACR重磅：PROTAC分子 ARV-110 、ARV-471结构公布]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:33:34 +0800</pubDate></item><item><title>直播预告 | 2021 AACR研发投资新机会</title><link>https://mp.weixin.qq.com/s/mDddCKqOyfbbSqDfMoHG3A</link><description></description><content:encoded><![CDATA[直播预告 | 2021 AACR研发投资新机会]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:33:34 +0800</pubDate></item><item><title>国家知识产权局：苹果酸舒尼替尼晶型专利全部无效</title><link>https://mp.weixin.qq.com/s/pOVUKUbAJvCYEg6O2BKDHg</link><description></description><content:encoded><![CDATA[国家知识产权局：苹果酸舒尼替尼晶型专利全部无效]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:33:34 +0800</pubDate></item><item><title>康宁杰瑞在AACR 2021年会上公布KN046联合白蛋白紫杉醇治疗三阴乳腺癌的临床研究数据</title><link>https://mp.weixin.qq.com/s/uEEL2BH_AXDcQrtKH6BJyQ</link><description></description><content:encoded><![CDATA[康宁杰瑞在AACR 2021年会上公布KN046联合白蛋白紫杉醇治疗三阴乳腺癌的临床研究数据]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:33:34 +0800</pubDate></item><item><title>新疆“2+4”联盟集采，约定采购量随企业降幅增加</title><link>https://mp.weixin.qq.com/s/txIcVrUfz4rgXihfqwho2w</link><description></description><content:encoded><![CDATA[新疆“2+4”联盟集采，约定采购量随企业降幅增加]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:33:34 +0800</pubDate></item><item><title>盘点：这9款中国公司开发的创新药已在美国申报上市</title><link>https://mp.weixin.qq.com/s/2Ux5r-hBW6y6BLJd10FMHg</link><description></description><content:encoded><![CDATA[盘点：这9款中国公司开发的创新药已在美国申报上市]]></content:encoded><pubDate>Sat, 10 Apr 2021 09:29:06 +0800</pubDate></item><item><title>LAG-3 疗法获FDA快速通道资格，一线治疗头颈部鳞状细胞癌</title><link>https://mp.weixin.qq.com/s/dtWkssJptnDFPLYmc0fiig</link><description></description><content:encoded><![CDATA[LAG-3 疗法获FDA快速通道资格，一线治疗头颈部鳞状细胞癌]]></content:encoded><pubDate>Sat, 10 Apr 2021 09:29:06 +0800</pubDate></item><item><title>豪森「阿美替尼」拟纳入突破性疗法，一线治疗NSCLC</title><link>https://mp.weixin.qq.com/s/XUeqVBA9HOxfsoXFKMZJlA</link><description></description><content:encoded><![CDATA[豪森「阿美替尼」拟纳入突破性疗法，一线治疗NSCLC]]></content:encoded><pubDate>Sat, 10 Apr 2021 09:29:06 +0800</pubDate></item><item><title>第四批国采，8省已确定执行时间</title><link>https://mp.weixin.qq.com/s/TetwViTH0GtChISH6D6pXg</link><description></description><content:encoded><![CDATA[第四批国采，8省已确定执行时间]]></content:encoded><pubDate>Sat, 10 Apr 2021 09:29:06 +0800</pubDate></item><item><title>辉瑞BCMA/CD3双抗申报临床</title><link>https://mp.weixin.qq.com/s/bCrBQyvRLUZXyjcLGt5hkQ</link><description></description><content:encoded><![CDATA[辉瑞BCMA/CD3双抗申报临床]]></content:encoded><pubDate>Sat, 10 Apr 2021 09:29:06 +0800</pubDate></item><item><title>首个伊布替尼仿制药申报上市！原研2020年销售额94亿美元</title><link>https://mp.weixin.qq.com/s/OxcsbuLuaDjng-YdsRpZiw</link><description></description><content:encoded><![CDATA[首个伊布替尼仿制药申报上市！原研2020年销售额94亿美元]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>基石药业「普拉替尼胶囊」新适应症上市申请拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/ZyUAitOlkN4x0NB6RIWetA</link><description></description><content:encoded><![CDATA[基石药业「普拉替尼胶囊」新适应症上市申请拟纳入优先审评]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>国内企业首家——朗来科技P2X3受体选择性拮抗剂临床申请正式受理</title><link>https://mp.weixin.qq.com/s/WXJv3URhHH-lGeKkoQ8MMw</link><description></description><content:encoded><![CDATA[国内企业首家——朗来科技P2X3受体选择性拮抗剂临床申请正式受理]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>国内首个CD70抗体药物申报临床</title><link>https://mp.weixin.qq.com/s/ssLOz2ZTx-GjgvVvSlw7pw</link><description></description><content:encoded><![CDATA[国内首个CD70抗体药物申报临床]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item></channel></rss>